The European Commission is expected to make a decision on Kisqali's approval in this setting in the next two months.

The expert recommendations addressed clinical workflow, guideline creation, and reimbursement barriers to precision oncology.

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

The firms aim to use Azure AI to process clinical notes, lab tests, genomic data, images, and other often inaccessible data to identify personalized treatments.

The company, which recently completed dosing TN-201 in an initial cohort of patients in the Phase Ib/II trial, will advance the study to the next dosing cohort.

The test is designed to identify various obesity phenotypes that doctors can use to personalize treatment plans.

NEW YORK – The UK's National Institute for Health and Care Excellence (NICE) on Wednesday recommended Genentech's ALK inhibitor Alecensa (alectinib) as an adjuvant therapy option for certain ...

NEW YORK – MeiraGTx on Tuesday said it plans to advance a gene therapy candidate it's developing for Parkinson's disease, AAV-GAD, into a Phase III trial based on positive data from a clinical ...

Academic researchers' efforts to advance CAR T-cell immunotherapy research in this partnership recently received a boost from PICI.

The investment will support development of radioligand therapies for cancer based on lead-212 alpha-emitting isotopes.